391 related articles for article (PubMed ID: 15222773)
1. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.
Phillips CJ
CNS Drugs; 2004; 18(9):561-74. PubMed ID: 15222773
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
[TBL] [Abstract][Full Text] [Related]
4. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
Chilcott J; McCabe C; Tappenden P; O'Hagan A; Cooper NJ; Abrams K; Claxton K; Miller DH;
BMJ; 2003 Mar; 326(7388):522; discussion 522. PubMed ID: 12623909
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.
Kendrick M; Johnson KI
Pharmacoeconomics; 2000 Jul; 18(1):45-53. PubMed ID: 11010603
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.
Tappenden P; McCabe C; Chilcott J; Simpson E; Nixon R; Madan J; Fisk JD; Brown M
Value Health; 2009; 12(5):657-65. PubMed ID: 19508662
[TBL] [Abstract][Full Text] [Related]
9. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
11. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
Tappenden P; Chilcott JB; Eggington S; Oakley J; McCabe C
Health Technol Assess; 2004 Jun; 8(27):iii, 1-78. PubMed ID: 15215017
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
Curtiss FR
J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
[No Abstract] [Full Text] [Related]
15. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
Hawton A; Shearer J; Goodwin E; Green C
Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
[TBL] [Abstract][Full Text] [Related]
16. Health outcomes in multiple sclerosis.
Flachenecker P; Rieckmann P
Curr Opin Neurol; 2004 Jun; 17(3):257-61. PubMed ID: 15167058
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.
Amato MP
Expert Opin Pharmacother; 2004 Oct; 5(10):2115-26. PubMed ID: 15461547
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.
Boggild M; Palace J; Barton P; Ben-Shlomo Y; Bregenzer T; Dobson C; Gray R
BMJ; 2009 Dec; 339():b4677. PubMed ID: 19955128
[TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
Parkin D; Jacoby A; McNamee P; Miller P; Thomas S; Bates D
J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):144-9. PubMed ID: 10644777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
